ACTRN12612000327886尚未招募未知
Circulating Tumour DNA as a marker of complete pathological response and long term outcome for locally advanced rectal cancer treated with pre-operative chemoradiotherapy.
udwig Institute for Cancer Research0 个研究点目标入组 320 人开始时间: 2012年3月21日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Patients with histologically confirmed adenocarcinoma of the rectum
- •2. Patients with radiologically defined locally advanced disease on pelvic MRI (mT3, mT4 or mN+) or endorectal ultrasound (uT3, uT4 or uN1) where MRI is contraindicated)
- •3. No evidence of metastatic disease on CT chest/abdomen/pelvis
- •4. Patients planned to receive long-course chemoradiation followed by curative surgery and adjuvant 5-fluorouracil or capecitabine chemotherapy
- •5. Patients willing to provide written informed consent
排除标准
- •1. History of another primary cancer within the last 5 years, with the exception of nonmelanomatous skin cancer and carcinoma in situ of the cervix.
- •2. Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol
- •3. Patients with major organ impairment
- •4. Patients that are not accessible for follow-up
研究者
相似试验
招募中
不适用
Circulating Tumour DNA as a Sensitive and Specific Marker of Response to Therapy and of Occult Disease in Colorectal CancerPatients with resectable colorectal cancer liver metastasesCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12612000345886udwig Institute for Cancer Research100
招募中
不适用
Circulating Tumour DNA in Stage 1 to 4 Ovarian CancerOvarian cancerACTRN12617001119381Walter and Eliza Hall Institute of Medical Research100
招募中
不适用
Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patientsmetastatic prostate cancerNL-OMON24467Erasmus Medical Center95
招募中
不适用
Circulating Tumour DNA as a Marker of Occult Disease in Stage II Colorectal Cancer and Response to Therapy in Metastatic Colorectal CancerMeasuring cancer specific gene changes in the blood as a biomarker in monitoring disease status in stage II and IV colorectal cancer.Cancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12612000326897udwig Institute for Cancer Research290
已完成
不适用
Quantification of Circulating tumor DNA derived Structural variants to assess treatment response in metastatic prostate cancer patientsprostate carcinoma10038364prostate cancerNL-OMON43524Erasmus MC, Universitair Medisch Centrum Rotterdam285